Adverse Outcome Pathways (AOPs) describe the mechanistic interactions of biological entities with a stressor (chemical, nanomaterial, radiation, virus, etc.) that produce an adverse response. How these interactions and associations are catalogued contributes to our ability to understand mechanistic effects and apply this knowledge to New Approach Methods (NAMs) that have the potential to reduce animal testing in chemical, biological, and material safety assessments. Making AOP data align with FAIR (Findable, Accessible, Interoperable, and Reusable) metadata standards relies on technical tools that implement and process AOP data and related metadata, and the establishment of coordinated and consensus computational bioinformatic methods. Herein current efforts in addressing the FAIRification of AOP mechanistic data and metadata, as well as the international, collaborative efforts to document, and improve the (re)-use and reliability of AOP information will be described. These coordinated efforts contribute to the establishment of a directive for the processing and storing of standardized AOP mechanistic data in the AOP-Wiki repository, and application of these data to next generation risk assessment.
Introduction: Systematic reviews (SR) collect and integrate data corpuses into consistent, computable, and comparable datasets. The adverse outcome pathway (AOP) framework facilitates the linking of data describing molecular initiating events, through one or more key events (KEs), to adverse biological outcomes. To explore the potential application of data from SRs to the AOP framework, a case study was conducted to explore mapping SR to existing AOP KEs. Methods: SR data consisted of in vitro and in vivo androgen receptor (AR) toxicity information from nonmammalian vertebrate species collected as described by the authors, limiting data comparability. Data were standardized and mapped to terms for Level of Biological Organization, Object, Process, and Action using existing KEs in the AOP-Wiki as a source for endpoint terms. Results: In vitro SR data had 131 of 264 records that mapped to AR transactivation, while in vivo data had 226 of 1891 records directly mappable to 31 different KEs (e.g., increased vitellogenin messenger RNA). When no appropriate terms existed in the AOP-Wiki, standardized terms were proposed for future use. For unstructured data, mapping and standardization required additional interpretation. Conclusions: This study highlights the difficulties in aligning heterogeneously extracted SR data with a structured framework. This work highlights the need for language standardization and the adoption of clear data collection guidance prior to, and during, the SR to enhance data comparability and computability. The adoption of such efforts can advance the ability of resulting data to be reused and applied to frameworks such as AOPs. Lessons learned in this case study are applicable to similar efforts examining the use of automation in data extraction and evaluation.